retatrutide triple agonist glp-1 gip glucagon phase 2 obesity trial Retatrutide—A Game Changer in Pharmacotherapy What Is Retatrutide? The Triple
Description
PMID: 36462999 Contreras C et al (2017): Traveling from the hypothalamus to the adipose tissue: The thermogenic pathway
Eating disorders and disordered eating in type 1 diabetes: prevalence, screening, and treatment options
The expansion targets 11 states where Humana already operates, planning to add center density in existing markets
This lets you capture the benefits of GLP-1 agonism at lower cost
